115 related articles for article (PubMed ID: 23847381)
21. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
Graziani G; Tentori L; Navarra P
Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
[TBL] [Abstract][Full Text] [Related]
22. Ipilimumab-Induced Granulomatous Disease Occurring Simultaneously With Disease Progression in a Patient With Metastatic Melanoma.
Toumeh A; Sakhi R; Shah S; Arudra SK; De Las Casas LE; Skeel RT
Am J Ther; 2016; 23(4):e1068-71. PubMed ID: 25933140
[TBL] [Abstract][Full Text] [Related]
23. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
van den Eertwegh AJ; Versluis J; van den Berg HP; Santegoets SJ; van Moorselaar RJ; van der Sluis TM; Gall HE; Harding TC; Jooss K; Lowy I; Pinedo HM; Scheper RJ; Stam AG; von Blomberg BM; de Gruijl TD; Hege K; Sacks N; Gerritsen WR
Lancet Oncol; 2012 May; 13(5):509-17. PubMed ID: 22326922
[TBL] [Abstract][Full Text] [Related]
24. Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: a randomized phase II trial.
Ravaud A; Delaunay M; Chevreau C; Coulon V; Debled M; Bret-Dibat C; Courbon F; Gualde N; Nguyen Bui B
Br J Cancer; 2001 Nov; 85(10):1467-71. PubMed ID: 11720430
[TBL] [Abstract][Full Text] [Related]
25. Relative Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor, Dacarbazine, and Glycoprotein 100 in Metastatic Melanoma: An Indirect Treatment Comparison.
Quinn C; Ma Q; Kudlac A; Palmer S; Barber B; Zhao Z
Adv Ther; 2017 Feb; 34(2):495-512. PubMed ID: 28000169
[TBL] [Abstract][Full Text] [Related]
26. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
27. A sequential four-drug chemotherapy and biotherapy with interferon alpha and GM-CSF--an innovative protocol for the treatment of metastatic melanoma.
Schachter J; Rakowsky E; Sulkes A; Adler A
Cancer Biother Radiopharm; 1998 Jun; 13(3):155-64. PubMed ID: 10850351
[TBL] [Abstract][Full Text] [Related]
28. Trial watch: ipilimumab success in melanoma provides boost for cancer immunotherapy.
Nat Rev Drug Discov; 2010 Aug; 9(8):584. PubMed ID: 20671754
[No Abstract] [Full Text] [Related]
29. Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma.
Ranganath HA; Panella TJ
J Immunother; 2015 Jun; 38(5):211. PubMed ID: 25962109
[TBL] [Abstract][Full Text] [Related]
30. Alterations in phenotype and cell-surface antigen expression levels of human monocytes: differential response to in vivo administration of rhM-CSF or rhGM-CSF.
Schmid I; Baldwin GC; Jacobs EL; Isacescu V; Neagos N; Giorgi JV; Glaspy JA
Cytometry; 1995 Jun; 22(2):103-10. PubMed ID: 7587740
[TBL] [Abstract][Full Text] [Related]
31. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
O'Day SJ; Atkins MB; Boasberg P; Wang HJ; Thompson JA; Anderson CM; Gonzalez R; Lutzky J; Amatruda T; Hersh EM; Weber JS
J Clin Oncol; 2009 Dec; 27(36):6207-12. PubMed ID: 19917850
[TBL] [Abstract][Full Text] [Related]
32. Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node.
van den Hout MF; Sluijter BJ; Santegoets SJ; van Leeuwen PA; van den Tol MP; van den Eertwegh AJ; Scheper RJ; de Gruijl TD
Cancer Immunol Immunother; 2016 Apr; 65(4):405-15. PubMed ID: 26935057
[TBL] [Abstract][Full Text] [Related]
33. Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor.
Daud AI; Mirza N; Lenox B; Andrews S; Urbas P; Gao GX; Lee JH; Sondak VK; Riker AI; Deconti RC; Gabrilovich D
J Clin Oncol; 2008 Jul; 26(19):3235-41. PubMed ID: 18591558
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20).
McDermott D; Haanen J; Chen TT; Lorigan P; O'Day S;
Ann Oncol; 2013 Oct; 24(10):2694-2698. PubMed ID: 23942774
[TBL] [Abstract][Full Text] [Related]
35. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma.
Spitler LE; Weber RW; Allen RE; Meyer J; Cruickshank S; Garbe E; Lin HY; Soong SJ
J Immunother; 2009; 32(6):632-7. PubMed ID: 19483646
[TBL] [Abstract][Full Text] [Related]
36. Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma.
Weber RW; O'Day S; Rose M; Deck R; Ames P; Good J; Meyer J; Allen R; Trautvetter S; Timmerman M; Cruickshank S; Cook M; Gonzalez R; Spitler LE
J Clin Oncol; 2005 Dec; 23(35):8992-9000. PubMed ID: 16260693
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
38. [Ipilimumab treatment of metastatic melanoma].
Ghasemi H; Schmidt H; Stolle LB
Ugeskr Laeger; 2015 Jan; 177(2A):108-9. PubMed ID: 25612993
[TBL] [Abstract][Full Text] [Related]
39. Comparisons of therapeutic efficacy and safety of ipilimumab plus GM-CSF versus ipilimumab alone in patients with cancer: a meta-analysis of outcomes.
Chen P; Chen F; Zhou B
Drug Des Devel Ther; 2018; 12():2025-2038. PubMed ID: 30013322
[TBL] [Abstract][Full Text] [Related]
40. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).
Weber J
Oncologist; 2008; 13 Suppl 4():16-25. PubMed ID: 19001147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
